Share on

Global BCG Vaccine Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Demographics, Product Type, End User, Applications & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 5015
Pages: 175
Formats: report pdf report excel report power bi report ppt

Global BCG Vaccine Market Size (2022 to 2027)

The global BCG vaccine market size is predicted to reach USD 58.86 Billion by 2027, to grow at a CAGR of 5.1% from 2022 to 2027.

BCG vaccine stands for Bacillus Calmette-Gurin (BCG) vaccine. It prevents TB and is the only vaccine in the market, which could do that. A single dose is given to an infant soon after birth in countries with a high occurrence of TB. In countries in which TB is not a common occurrence, only high-risk infants are treated with it. Adults are only treated with this vaccine if their exposure to drug-resistant TB is a regular occurrence.

Albert Calmette and Camille Guérin produced the original strain of BCG in 1924 at the Pasteur Institute. BCG vaccine is used against Tuberculosis. Tuberculosis is a severe infection, which causes by the lungs, sometimes in other parts of the body. Vaccine Dose is given to healthy babies after birth because, at that age, they are at high risk of getting immunized. The Bacille Calmette-Guerin vaccine is one of the most widely used as per the current vaccines. It is a part of the national childhood immunization program. The BCG vaccine included types that are Immune BCG and Therapy BCG. BCG vaccine is also used to treat other mycobacterial infections, such as Buruli ulcer diseases. The World Health Organization (WHO) estimates that TB caused to 10million people and claimed 1.6 million lives in 2017.


The increasing number of TB cases worldwide, particularly in the developing countries of APAC, rapid advancements in technology in the field of medical research on vaccines, and favorable government policies and initiatives with improved funding are driving the growth of the global BCG vaccine market.

The demand for BCG vaccines is increasing day by day, as the rising birth rate population. Also, the spread rate of Tuberculosis in the adult stage of the community will boost the demand in the forecast period. The stage-wise vaccines for Tuberculosis have a higher need in the future. The increasing epidemic of diseases in the future can decide the rising demand for the BCG Vaccine and BCG vaccine pipeline evolution, which will influence supply and demand dynamics. 

Recently, WHO Preferred product characteristics, document for new development an upcoming vaccine for Tuberculosis; the primary concern to create this vaccine was to protect pulmonary TB in adults, and the production of new TB vaccine with better efficacy and safety than BCG to control neonates and infants. Currently, in an investigation was found that the TB vaccine participant (M72/AS01E) was found protected against TB in clinical trial Phase II was conducted in Kenya, Zambia, and South Africa with the evidence of latent tuberculosis infection the trial was conducted by the Glaxo Smith Klein (GSK). By focusing on the regional expansion, leading segments, key opportunities, and rising trends and vendor landscape, the Freeze-Dried BCG vaccine market has incredible growth possibilities. Continuous inspection of those studies is reasonable to ensure that the procurement practices allow sufficient time for supply adjustments. 


The key restraint for the global BCG vaccine market is continuous supply availability.

UNICEF reported the shortfall of 16.7 million vaccines due to the less supply capacity. As well as the inflexibility in demand gives the challenge to the industry. Middle-income countries are also facing the supply, and in high-income countries, there is no further happened after the first strain. The limited investments in the production of vaccines by the Government also affect the supply and production. 

There are three risks mitigating interventions in three areas: sharing, enhancing information between major health sectors, working with other countries in tighter vaccine management, and Expanding investments in the BCG manufacturing process. Furthermore, adverse side-effects of this vaccine and supply bottlenecks worldwide are expected to hinder market growth in the forecast period.

Impact of COVID-19 on the global BCG vaccine market:

The COVID-19 has disrupted the global economy drastically. The World Health Organization (WHO) declared COVID 19 as a pandemic that has spread to around 203 countries globally. Lockdown has affected so many industries in several ways, where some industries got impacted badly, some gained profits. The Bacillus Calmette-Gurin (BCG) Vaccine Market has seen some profits. The BCG vaccine is used to prevent tuberculosis (TB), but some researchers have announced that the BCG vaccine can be used for COVID treatment, fuelling the market. But the BCG vaccine is not a perfect cure for COVID; it is just used as an immediate medication to prevent deaths. All the COVID-affected older people got vaccinated in countries like India, which propelled the BCG vaccine market. Few countries had done some clinical trials on humans to see the BCG vaccine's effectiveness, boosting the market growth. These are the factors that helped the BCG Vaccine Market growth during COVID. The Key Players in the market have done a great job by increasing BCG vaccine production during the pandemic.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Analysed

By Demography, Product Type, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Companies Analysed

Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institute.


This research report on the global BCG vaccine market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2027.

BCG Vaccine Market - By Demographics:

  • Pediatrics (0-18 years)        
  • Adults (19-35 years)            

Based on demography, Paediatrics is a clear market leader accounting for more than three-quarters of the market share and is likely to gain even more in the forecast period. BCG vaccine is infused to children in many countries just after the months of lactation. The vaccine is compulsory for infants in the countries where there is a prevalence of TB. Hence, the pediatrics segment leads the market in all the countries.

BCG Vaccine Market - By Product Type:

  • Immune BCG         
  • Therapy BCG          

Based on product type, the immune BCG segment is expected to lead the market during the forecast period. It is because BCG vaccination has become mandatory in most countries as part of the national immunization program. Moreover, the efficacy of the vaccine is reduced if it is not administered in infancy. The usage of this vaccine is highest in Kenya. Polio and hepatitis B vaccines are usually administered alongside it.

BCG Vaccine Market - By End User:

  • Pediatrics 
  • Adults       

BCG Vaccine Market - By Application:

  • Home        
  • Commercial       

Based on the application, the commercial segment leads the market, which can be attributed to administering the vaccine in hospitals to infants. Governments are also procuring vaccine candidates on a large scale.

BCG Vaccine Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Geographically, the North America leads the market in the segment; this can be attributed to the sophisticated health care and government policies towards eradicating TB. Though the prevalence of TB is less in this region, proper care and vaccination are being taken place in this region. Eastern EU region with Germany has more TB prevalence rate, and there is more market for the BCG vaccine market.  

At the same time, Asia Pacific is expected to grow with the highest CAGR due to TB eradication campaigns in developing countries. Asia Pacific is the second most lucrative market for BCG vaccines; due to tropical lying countries like India, Japan, and Malaysian countries, TB prevalence is more in this region; around 40% of the worlds TB population lies in this region. As a result, this provides ample scope for the BCG vaccine market to expand in this region.

In the Latin American region, countries like Brazil and Argentina are good markets for the BCG vaccine market as the TB prevalence rate in these regions is high.

The middle east and Africa, especially the African continent, is a breeder house for tuberculosis, and many countries, along with WHO, have framed many TB eradication programs. Hence, they provide a large market for the BCG vaccine. In the middle east region, Gulf countries have framed TB eradication programs to secure the people with transmission from African people; these countries also contribute for the market to expand further in this region.


Some of the notable companies operating in the global BCG vaccine market profiled in the report are Merck & Co., Inc, Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd, InterVax Ltd, GreenSignal Bio Pharma Limited (GSBPL), Statens Serum Institute


  • On 24 February 2021, Sanofi S.A., a French multinational pharmaceutical company that was initially established in 1973, merged with Synthélabo in 1999 to form Sanofi-Synthélabo, and GSK (GlaxoSmithKline plc) has announced that they are going to initiate the Phase II study with 720 volunteers aged 18 and over for selecting the most appropriate antigen dosage for Phase III evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate.
  • In February 2021, Serum Institute of India, one of the key players in the Global BCG Vaccine Market, said that they had initiated the COVID-19 vaccine Covishield to COVAX, which is the global initiative formed to provide rapid and equitable access to the vaccine to all the countries around the globe. The CEO of SII (Serum Institute of India), Adar Poonawalla, has tweeted that it is a historic moment for them as the COVAX receives its first doses of the Oxford-AstraZeneca vaccine manufactured by SII, COVISHIELD.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample